Teresa Puig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Teresa Puig has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ramon Colomer
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, 28006 Madrid, Spain
2 shared publications A. Blancafort
Institut d’Investigació Biomèdica de Girona – Facultat de Medicina, Girona, Spain
1 shared publication- Ander Urruticoechea
Biogipuzkoa (previously known as Biodonostia) Health Research Institute, San Sebastián, Spain; Gipuzkoa Cancer Unit/OSI Donostialdea - Onkologikoa, San Sebastián, Spain
1 shared publication - Daniel Gómez-Cabello
Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain
1 shared publication G. Oliveras
Institut d'Investigació Biomèdica de Girona - Facultat de Medicina, Girona, Spain
1 shared publication- Maria Luz Lopez Rodriguez
Departamento de Química Orgánica I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
1 shared publication
Latest Publications
- 25 October 2010
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1210 (1) , 86-92
Novel anti‐fatty acid synthase compounds with anti‐cancer activity in HER2+ breast cancer
Fatty acid synthase (FASN) expression and activity has emerged as a common phenotype in most human carcinomas, including breast cancer, and its expression is tightly linked to HER2 signaling pathways. The development of inhibitors of FASN activity has consequently appeared as a novel antitarget modality for treating cancer. However, the clinical use of FASN inhibitors, such as cerulenin, C75, and epigallocatechin 3‐gallate (EGCG), is limited by anorexia and induced body weight loss or by its low in vivo potency and stability. Here, we summarize the design and development of G28UCM, the lead‐compound of a novel family of synthetic FASN inhibitors, with both in vitro and in vivo activity in a human breast cancer model of FASN+ and HER2+.
- 25 October 2010
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1210 (1) , 86-92
Novel anti‐fatty acid synthase compounds with anti‐cancer activity in HER2+ breast cancer
Fatty acid synthase (FASN) expression and activity has emerged as a common phenotype in most human carcinomas, including breast cancer, and its expression is tightly linked to HER2 signaling pathways. The development of inhibitors of FASN activity has consequently appeared as a novel antitarget modality for treating cancer. However, the clinical use of FASN inhibitors, such as cerulenin, C75, and epigallocatechin 3‐gallate (EGCG), is limited by anorexia and induced body weight loss or by its low in vivo potency and stability. Here, we summarize the design and development of G28UCM, the lead‐compound of a novel family of synthetic FASN inhibitors, with both in vitro and in vivo activity in a human breast cancer model of FASN+ and HER2+.
- 1 March 2009
- Published by Elsevier in Medicina Clinica
- Vol. 132 (9) , 359-363
Sintasa de ácidos grasos como nueva diana antitumoral
- 1 March 2009
- Published by Elsevier in Medicina Clinica
- Vol. 132 (9) , 359-363
Sintasa de ácidos grasos como nueva diana antitumoral